Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population‐Based Analysis (2020–2023)
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70527 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 25.05.2026. Verfasst von Kenichi Sasaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyorin University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Deamino Arginine Vasopressin, Polyuria, Antidiuretic Agents, Nocturia. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
Desmopressin is an established treatment for nocturia due to nocturnal polyuria. In Japan, low‐dose formulations (25 and 50 μg) were approved only for men in 2019. However, age‐ and dose‐specific prescribing patterns in real‐world practice remain unclear. Using nationwide aggregated claims data, we analyzed age‐stratified prescribing trends and dose selection patterns.
Methods
Publicly available NDB Open Data (fiscal years 2020–2023) were used. Outpatient prescriptions for desmopressin orally disintegrating tablets (25 and 50 μg) were extracted by sex and 5‐year age categories. Population‐adjusted prescription rates per 1000 persons and 95% confidence intervals (CIs) were calculated. Temporal trends were evaluated using Poisson regression models with log‐population offset.
Results
In men, the population‐adjusted prescription rate increased from 21.5 per 1000 persons in 2020 to 84.6 in 2023 ( p for trend < 0.001). More than 90% of prescriptions were issued to individuals aged ≥ 65 years. Overall, use of the 25 and 50 μg formulations was balanced; however, the proportion of the 25 μg formulation increased with advancing age, and the 25 μg/50 μg ratio reached 1.37 among those aged ≥ 90 years. Prescriptions in women also increased, with predominance of the 25 μg formulation.
Conclusions
Desmopressin prescribing has increased nationwide in Japan, particularly among older men. Increased selection of the lower‐dose formulation in older patients may reflect safety considerations. Off‐label use in women is increasing, indicating the need for further safety evaluation and appropriate prescribing guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Urology, Mishima General Hospital, Shizuoka, Japan.
ORCID-Profile: Motofumi Suzuki, Yu Nakamura, Manami Kinjo, Mitsuhiro Tambo
Zitieren
APA
Sasaki, K., Suzuki, M., Yamamoto, M., Sakamoto, T., Horikawa, Y., Kii, T., Kitamura, J., Nakamura, Y., Kinjo, M., Tambo, M., & Fukuhara, H. (2026). Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population‐Based Analysis (2020–2023). International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70527
Vancouver
Sasaki K, Suzuki M, Yamamoto M, Sakamoto T, Horikawa Y, Kii T, et al. Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population‐Based Analysis (2020–2023). International Journal of Urology. 2026;33(5). doi:10.1111/iju.70527
BibTeX
@article{Sasaki2026,
author = {Sasaki, Kenichi and Suzuki, Motofumi and Yamamoto, Masahiro and Sakamoto, Takamasa and Horikawa, Yukiyasu and Kii, Toshihiko and Kitamura, Junji and Nakamura, Yu and Kinjo, Manami and Tambo, Mitsuhiro and Fukuhara, Hiroshi},
title = {Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population‐Based Analysis (2020–2023)},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70527}
}
EUVIMED